Skip to Content
Merck
CN

EHU009671

MISSION® esiRNA

targeting human PKN3

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

MISSION® esiRNA, targeting human PKN3

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GACCTCATGATGCAGATCCACGAGGATGTCTTCCCCGAGCCCCAGGCCCGCTTCTACGTGGCTTGTGTTGTCCTGGGGCTGCAGTTCTTACACGAGAAGAAGATCATTTACAGGGACCTGAAGTTGGATAACCTTCTGCTGGATGCCCAGGGATTCCTGAAGATCGCAGACTTTGGACTCTGCAAGGAAGGGATCGGCTTCGGGGACCGGACTAGCACCTTCTGTGGCACCCCGGAGTTCCTGGCTCCCGAGGTGCTGACCCAGGAGGCATACACACGGGCTGTGGACTGGTGGGGGCTGGGTGTGCTGCTCTACGAGATGCTGGTGGGTGAGTGCCCGTTCCCAGGGGACACAGAGGAAGAGGTGTTTGACTGCATCGTCAACATGGACGCCCCCTACCCCGGCTTTCTGTCGGTGCAAGGGCTTGAGTTCAT

Ensembl | human accession no.

ENSG00000160447

NCBI accession no.

NM_013355

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Gene Information

human ... PKN3(29941), PKN3(29941)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
JUU
ZNU
NRR
RPR

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoshiyuki Hattori et al.
Oncology letters, 14(5), 5157-5166 (2017-11-04)
It has been reported that suppression of protein kinase N3 (PKN3) expression in vascular and lymphatic endothelial cells results in the inhibition of tumor progression and lymph node metastasis formation. The present study investigated whether combination therapy of small interfering

Related Content

MISSION esiRNA

Instructions

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service